82 FR 17465 - Patient Release Program
NUCLEAR REGULATORY COMMISSION Federal Register Volume 82, Issue 68 (April 11, 2017)
Federal Register Volume 82, Issue 68 (April 11, 2017)
| Page Range | 17465-17467 | |
| FR Document | 2017-07276 |
[Federal Register Volume 82, Number 68 (Tuesday, April 11, 2017)] [Notices] [Pages 17465-17467] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-07276] ----------------------------------------------------------------------- NUCLEAR REGULATORY COMMISSION [NRC-2017-0094] Patient Release Program AGENCY: Nuclear Regulatory Commission. ACTION: Request for comment. ----------------------------------------------------------------------- SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) is requesting comment from the general public on its patient release programs. Specifically, the NRC would like input from the public on whether additional or alternate criteria are needed and whether to clarify the NRC's current patient release requirements. The information will be used to determine whether significant regulatory changes to the NRC's patient release requirements are warranted. DATES: Submit comments by June 12, 2017. Comments received after this date will be considered if it is practical to do so, but the NRC is able to assure consideration only for comments received on or before this date. ADDRESSES: You may submit comments by any of the following methods (unless this document describes a different method for submitting comments on a specific subject):Federal Rulemaking Web site: Go to http://www.regulations.gov and search for Docket ID NRC-2017-0094. Address questions about NRC dockets to Carol Gallagher; telephone: 301-415- 3463; email: [email protected]. For technical questions, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section of this document. Mail comments to: Cindy Bladey, Office of Administration, Mail Stop: OWFN-12-H08, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001. For additional direction on obtaining and submitting comments, see ``Obtaining Information and Submitting Comments'' in the SUPPLEMENTARY INFORMATION section of this document. FOR FURTHER INFORMATION CONTACT: Donna-Beth Howe, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001; telephone: 301-415-7848; email: [email protected]. SUPPLEMENTARY INFORMATION: I. Obtaining Information and Submitting Comments A. Obtaining Information Please refer to Docket ID NRC-2017-0094 when contacting the NRC about the availability of information for this action. You may obtain publicly-available information related to this action by any of the following methods: Federal Rulemaking Web site: Go to http://www.regulations.gov and search for Docket ID NRC-2017-0094. NRC's Agencywide Documents Access and Management System (ADAMS): You may obtain publicly-available documents online in the ADAMS Public Documents collection at http://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``ADAMS Public Documents'' and then select ``Begin Web-based ADAMS Search.'' For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or by email to [email protected]. The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that it is mentioned in the SUPPLEMENTARY INFORMATION section. NRC's PDR: You may examine and purchase copies of public documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. B. Submitting Comments Please include Docket ID NRC-2017-0094 in your submission. The NRC cautions you not to include identifying or contact information that you do not want to be publicly disclosed in your comment submission. The NRC posts all comment submissions at http://www.regulations.gov and enters the comment submissions into ADAMS. The NRC does not routinely edit comment submissions to remove identifying or contact information. If you are requesting or aggregating comments from other persons for submission to the NRC, then you should inform those persons not to include identifying or contact information that they do not want to be publicly disclosed in their comment submission. Your request should state that the NRC does not routinely edit comment submissions to remove such information before making the comment submissions available to the public or entering the comment submissions into ADAMS. II. Background In a March 10, 2014, Commission Action Memorandum (COMAMM-14-0001/ COMWDM-14-0001, ``Background and Proposed Direction to NRC Staff to Verify Assumptions Made Concerning Patient Release Guidance'' (ADAMS Accession No. ML14072A112), then NRC Chairman MacFarlane and then Commissioner Magwood brought into question, among other things, whether significant regulatory changes to the patient release program are warranted. They asked whether different criteria should be used to determine when patients should be released, whether the application of the current dose release standard needed to be clarified, whether all exposed members of the public should be subject to the same patient release dose limit, and whether new release requirements are needed for patients who are likely to expose young children and pregnant women. In the Staff Requirements Memorandum (SRM) to COMAMM-14-0001/ COMWDM-14-0001 (ADAMS Accession No. ML14118A387), the Commission, among other things, directed the NRC staff to evaluate whether regulatory changes are necessary to clarify the NRC's current release criteria and whether additional or alternate criteria are needed. As a result of earlier public comments on other elements of the SRM (November 16, 2015; 80 FR 70843), the staff identified two additional questions to consider. These are whether a requirement is needed to ensure the discussion between the licensee and patient concerning patient isolation occurs in sufficient time for licensees or patients to make necessary arrangements for holding or releasing the patient and whether patients required to receive instructions on minimizing dose to others should be provided with these instructions before the administration. The NRC is interested in obtaining input from as many stakeholders as possible, including the NRC's Advisory [[Page 17466]] Committee on the Medical Use of Isotopes, professional organizations, physicians, patients, patient advocacy groups, licensees, Agreement States, and other interested individuals. The focus of this request is to gather information that will permit the NRC staff to determine whether significant regulatory changes to the patient release program are warranted. During the comment period on April 25, 2017 and May 23, 2017, the NRC will have two public meeting at the NRC's Headquarters that will explain and clarify the information requested with members of the public. These meetings will be webcast. The NRC does not intend to provide any responses to comments received during the public meeting(s). The public meeting(s) will be noticed on the NRC's public meeting Web site at least 10 calendar days before the meeting. Members of the public should monitor the NRC's public meeting Web site at http://www.nrc.gov/public-involve/public-meetings/index.cfm. The NRC will also post the meeting notices on the Federal rulemaking Web site at http://www.regulations.gov under Docket ID NRC- 2017-0094. The NRC may post additional materials related to this document, including public comments, on the Federal rulemaking Web site. The Federal rulemaking Web site allows you to receive alerts when changes or additions occur in a docket folder. To subscribe: (1) Navigate to the docket folder (NRC-2017-0094); (2) click the ``Sign up for Email Alerts'' link; and (3) enter your email address and select how frequently you would like to receive emails (daily, weekly, or monthly). III. Requested Information and Comments A. Development of an Activity-Based Patient Release Threshold The NRC is asking the public to comment on whether the NRC should develop an activity-based patient release threshold under which patients would be required to be maintained in a clinic-sponsored facility (e.g., a medical facility or facility under the licensee's control) until the standard for release is met. Question: Should the NRC develop an activity-based patient release threshold? 1. If so, explain why and provide a potential activity-based criterion. 2. If not, explain why the regulations should remain as is. 3. In either case, describe the resulting health and safety benefits, or lack of benefits, to the individual being released and to individual members of the public. B. Clarification of the Time Covered by the Current Dose Limit in 10 CFR 35.75(a) for Releasing Individuals Currently, under section 35.75(a) of title 10 of the Code of Federal Regulations (10 CFR), allows a licensee to release a patient if the dose to any other individual is not likely to exceed 5 milliSieverts (mSv) (0.5 rem). The NRC staff determined in the NRC' Regulatory Issue Summary 2008-07, ``Dose Limit for Patient Release Under 10 CFR 35.75'' (ADAMS Accession No. ML063030572) that, as written the regulation is ambiguous and the dose to any other individual from the released individual does not reflect the NRC's intent of a per-year limit and that this limit has been interpreted by others to be per release. The NRC staff explained that a ``per release'' interpretation does not consider the cumulative dose received in a year from the same released individual or repeated exposure to different released individuals. The Commission has asked the NRC staff to clarify this issue. Question: Should the NRC amend the regulations to clarify the time frame for the current dose limit in 10 CFR 35.75(a) for releasing Individuals? For example, should the regulations explicitly state that the criterion is a per year limit? If not, is there a different criterion that the NRC should consider? In either case, describe the resulting health and safety benefits, or lack of benefit, to the individual being released and to individual members of the public as a result of the proposed clarification. C. Appropriateness of Applying the Same Limit on Dose From Patient Exposure to All Members of the General Public In the current NRC patient release dose criterion, the NRC does not distinguish between family members, young children, pregnant women, caregivers, hotel workers, and other members of the public. Further, the NRC patient release dose criterion is above the 10 CFR part 20 public dose limit. Question: Should the NRC continue to apply the same dose criteria of 5 mSv (0.5 rem), to all members of the general public, including family members, young children, pregnant women, caregivers, hotel workers, and other members of the public when considering the release of patients? 1. If so, explain why. 2. If not, what criterion should the NRC use for an individual group or groups? Specify the group (e.g., family members, young children, pregnant women, caregivers, hotel workers, or others) for each criterion. 3. In either case, describe the resulting health and safety benefits, or lack of benefits, to the individual being released and to individual members of the public. D. Requirements for Releasing Individuals Who Are Likely To Expose Young Children and Pregnant Women The current NRC patient release program requires the licensee to provide the released individual with instructions if the dose to any individual is likely to exceed 1 mSv (0.1 rem). The NRC does not have specific requirements for releasing patients who are likely to expose young children or pregnant women to doses above the public dose limit. Question: Should the NRC include a specific requirement for the release of a patient who is likely to expose young children or pregnant women to doses above the public dose limit? 1. If so, explain why and describe what the requirement should include. 2. If not, explain why the requirement is not needed. 3. In either case, describe the resulting health and safety benefits, or lack of benefits, to the individual being released and to a young child or to pregnant woman. E. Requirement for Timely Discussion With the Patient About Patient Isolation to Provide Time for Licensee and Patient Planning The current NRC patient release program permits the licensee to authorize the release from its control of any individual who has been administered unsealed byproduct material or implants containing byproduct material if the total effective dose equivalent to any other individual from exposure to the released individual is not likely to exceed 5 mSv (0.5 rem). In some common procedures (e.g., Iodine-131 procedures), the patients must isolate themselves for the licensee to meet this dose release requirement. In other cases, the patient cannot be released and the licensee must make arrangements to isolate the patient. The requirements are silent on when the licensee should discuss patient isolation with the patient. As a result, both patients and licensees may not have time to make appropriate isolation arrangements prior to the planned administration. Some patients reported that they were unaware of a need to isolate themselves from others prior to the administration. Question: Should the NRC have a specific requirement for the licensee to have a patient isolation discussion with patients in sufficient time prior to the [[Page 17467]] administration to provide the patient time to make isolation arrangements or the licensee to make plans to hold the patient, if the patient cannot be immediately released? 1. If so, explain why and describe what the requirement should include. 2. If not, explain why the requirement is not needed. 3. In either case, describe the resulting health and safety benefits, or lack of benefits, to individual being released, the licensee, and to the public. F. Requirement To Ensure Patients Are Given Instructions Prior to the Procedure The current NRC patient release regulations require the licensee to provide the released individual with instructions if the dose to any individual is likely to exceed 1 mSv (0.1 rem). The requirements are silent on when the required instructions should be given to the patient. Some patients are given instructions along with other medical release paperwork and may not be aware of the instructions. Question: Should the NRC explicitly include the time frame for providing instructions in the regulations (e.g., the instructions should be given prior to the procedure)? 1. If so, explain why and provide a recommended time period for the instructions to be provided. 2. If not, explain why the requirement is not needed. 3. In either case, describe the resulting health and safety benefits, or lack of benefits, to the individual being released, the licensee, and to the public. Dated at Rockville, Maryland, this 3rd day of April, 2017. For the Nuclear Regulatory Commission. Daniel S. Collins, Director, Division of Material Safety, State, Tribal and Rulemaking Programs, Office of Nuclear Material Safety and Safeguards. [FR Doc. 2017-07276 Filed 4-10-17; 8:45 am] BILLING CODE 7590-01-P
![Federal Register / Vol. 82, No. 68 / Tuesday, April 11, 2017 / Notices 17465
the Renewed Facility Operating License Regulatory Commission, Washington, If you are requesting or aggregating
and Technical Specifications. DC 20555–0001. comments from other persons for
Date of initial notice in Federal For additional direction on obtaining submission to the NRC, then you should
Register: August 16, 2016 (81 FR and submitting comments, see inform those persons not to include
54618). ‘‘Obtaining Information and Submitting identifying or contact information that
The Commission’s related evaluation Comments’’ in the SUPPLEMENTARY they do not want to be publicly
of the amendment is contained in a INFORMATION section of this document. disclosed in their comment submission.
Safety Evaluation dated March 24, 2017. FOR FURTHER INFORMATION CONTACT: Your request should state that the NRC
No significant hazards consideration Donna-Beth Howe, Office of Nuclear does not routinely edit comment
comments received: No. Material Safety and Safeguards, U.S. submissions to remove such information
Dated at Rockville, Maryland, this 31st day Nuclear Regulatory Commission, before making the comment
of March 2017. Washington, DC 20555–0001; telephone: submissions available to the public or
For the Nuclear Regulatory Commission. 301–415–7848; email: Donna- entering the comment submissions into
Kathryn M. Brock, Beth.Howe@nrc.gov. ADAMS.
Deputy Director, Division of Operating SUPPLEMENTARY INFORMATION: II. Background
Reactor Licensing, Office of Nuclear Reactor In a March 10, 2014, Commission
Regulation. I. Obtaining Information and Action Memorandum (COMAMM–14–
[FR Doc. 2017–07279 Filed 4–10–17; 8:45 am] Submitting Comments 0001/COMWDM–14–0001,
BILLING CODE 7590–01–P
A. Obtaining Information ‘‘Background and Proposed Direction to
NRC Staff to Verify Assumptions Made
Please refer to Docket ID NRC–2017–
Concerning Patient Release Guidance’’
NUCLEAR REGULATORY 0094 when contacting the NRC about
(ADAMS Accession No. ML14072A112),
COMMISSION the availability of information for this then NRC Chairman MacFarlane and
action. You may obtain publicly- then Commissioner Magwood brought
[NRC–2017–0094]
available information related to this into question, among other things,
Patient Release Program action by any of the following methods: whether significant regulatory changes
• Federal Rulemaking Web site: Go to to the patient release program are
AGENCY: Nuclear Regulatory http://www.regulations.gov and search warranted. They asked whether
Commission. for Docket ID NRC–2017–0094. different criteria should be used to
ACTION: Request for comment. • NRC’s Agencywide Documents determine when patients should be
Access and Management System released, whether the application of the
SUMMARY: The U.S. Nuclear Regulatory (ADAMS): You may obtain publicly-
Commission (NRC) is requesting current dose release standard needed to
available documents online in the be clarified, whether all exposed
comment from the general public on its ADAMS Public Documents collection at
patient release programs. Specifically, members of the public should be subject
http://www.nrc.gov/reading-rm/ to the same patient release dose limit,
the NRC would like input from the adams.html. To begin the search, select and whether new release requirements
public on whether additional or ‘‘ADAMS Public Documents’’ and then are needed for patients who are likely to
alternate criteria are needed and select ‘‘Begin Web-based ADAMS expose young children and pregnant
whether to clarify the NRC’s current Search.’’ For problems with ADAMS, women.
patient release requirements. The please contact the NRC’s Public In the Staff Requirements
information will be used to determine Document Room (PDR) reference staff at Memorandum (SRM) to COMAMM–14–
whether significant regulatory changes 1–800–397–4209, 301–415–4737, or by 0001/COMWDM–14–0001 (ADAMS
to the NRC’s patient release email to pdr.resource@nrc.gov. The Accession No. ML14118A387), the
requirements are warranted. ADAMS accession number for each Commission, among other things,
DATES: Submit comments by June 12, document referenced (if it is available in directed the NRC staff to evaluate
2017. Comments received after this date ADAMS) is provided the first time that whether regulatory changes are
will be considered if it is practical to do it is mentioned in the SUPPLEMENTARY necessary to clarify the NRC’s current
so, but the NRC is able to assure INFORMATION section. release criteria and whether additional
consideration only for comments • NRC’s PDR: You may examine and or alternate criteria are needed. As a
received on or before this date. purchase copies of public documents at result of earlier public comments on
ADDRESSES: You may submit comments the NRC’s PDR, Room O1–F21, One other elements of the SRM (November
by any of the following methods (unless White Flint North, 11555 Rockville 16, 2015; 80 FR 70843), the staff
this document describes a different Pike, Rockville, Maryland 20852. identified two additional questions to
method for submitting comments on a consider. These are whether a
B. Submitting Comments
specific subject): requirement is needed to ensure the
• Federal Rulemaking Web site: Go to Please include Docket ID NRC–2017– discussion between the licensee and
http://www.regulations.gov and search 0094 in your submission. patient concerning patient isolation
for Docket ID NRC–2017–0094. Address The NRC cautions you not to include occurs in sufficient time for licensees or
questions about NRC dockets to Carol identifying or contact information that patients to make necessary
Gallagher; telephone: 301–415–3463; you do not want to be publicly arrangements for holding or releasing
email: Carol.Gallagher@nrc.gov. For disclosed in your comment submission. the patient and whether patients
srobinson on DSK5SPTVN1PROD with NOTICES
technical questions, contact the The NRC posts all comment required to receive instructions on
individual listed in the FOR FURTHER submissions at http:// minimizing dose to others should be
INFORMATION CONTACT section of this www.regulations.gov and enters the provided with these instructions before
document. comment submissions into ADAMS. the administration.
• Mail comments to: Cindy Bladey, The NRC does not routinely edit The NRC is interested in obtaining
Office of Administration, Mail Stop: comment submissions to remove input from as many stakeholders as
OWFN–12–H08, U.S. Nuclear identifying or contact information. possible, including the NRC’s Advisory
VerDate Sep<11>2014 20:18 Apr 10, 2017 Jkt 241001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 E:\FR\FM\11APN1.SGM 11APN1](https://thefederalregister.org/doc/82_FR_17533/page/1.svg)
![Federal Register / Vol. 82, No. 68 / Tuesday, April 11, 2017 / Notices 17467
administration to provide the patient invites public comment, and takes other projections of expected revenue.4 The
time to make isolation arrangements or administrative steps. Commission denied the request for
the licensee to make plans to hold the DATES: Comments are due: April 26, exemption as premature, but noted that
patient, if the patient cannot be 2017. the Postal Service may resubmit its
immediately released? request ‘‘once it collects sufficient data
1. If so, explain why and describe ADDRESSES: Submit comments to calculate the total revenue received
what the requirement should include. electronically via the Commission’s and estimate the additional revenue
2. If not, explain why the requirement Filing Online system at http:// anticipated for each fiscal year of the
is not needed. www.prc.gov. Those who cannot submit market test.’’ Order No. 2224 at 18.
3. In either case, describe the resulting comments electronically should contact The Postal Service asserts that it now
health and safety benefits, or lack of the person identified in the FOR FURTHER has the data available to make the
benefits, to individual being released, INFORMATION CONTACT section by calculations requested by the
the licensee, and to the public. telephone for advice on filing Commission. Request at 3. The Postal
alternatives. Service states that if current demand for
F. Requirement To Ensure Patients Are
FOR FURTHER INFORMATION CONTACT: Customized Delivery continues, it
Given Instructions Prior to the
David A. Trissell, General Counsel, at anticipates reaching the inflation
Procedure
202–789–6820. adjusted $10 million revenue limitation
The current NRC patient release for FY 2017 in early June 2017.5
SUPPLEMENTARY INFORMATION: On April
regulations require the licensee to The Commission shall approve the
4, 2017, the Postal Service filed a
provide the released individual with request for exemption if it determines
request, pursuant to 39 U.S.C.
instructions if the dose to any that: (1) The product is likely to benefit
3641(e)(2), for an exemption from the
individual is likely to exceed 1 mSv (0.1 the public and meet an expected
$10 million annual revenue limitation
rem). The requirements are silent on demand; (2) the product is likely to
for the Customized Delivery market
when the required instructions should contribute to the financial stability of
test.1 The Commission authorized the
be given to the patient. Some patients the Postal Service; and (3) the product
market test to proceed in Order No.
are given instructions along with other is unlikely to result in unfair or
2224 and authorized the extension of
medical release paperwork and may not otherwise inappropriate competition. 39
the market test in Order No. 3543 until
be aware of the instructions. U.S.C. 3641(e)(2). In its Request, the
Question: Should the NRC explicitly October 31, 2017.2
Postal Service discusses how the
include the time frame for providing The Postal Service states that
Customized Delivery market test
instructions in the regulations (e.g., the ‘‘Customized Delivery is an
benefits the public and meets an
instructions should be given prior to the experimental package delivery service
expected demand, contributes to the
procedure)? that offers delivery of groceries and
Postal Service’s financial stability, and
1. If so, explain why and provide a other prepackaged goods within a
is unlikely to result in unfair or
recommended time period for the customized delivery window.’’ Request
inappropriate competition. Request at
instructions to be provided. at 4. The Postal Service states that the
5–7. The Commission’s regulations
2. If not, explain why the requirement purpose of the market test is to test and
require the Postal Service to file cost
is not needed. develop a long-term, scalable solution to
and revenue information with its
3. In either case, describe the resulting facilitate expansion to additional
request for exemption. 39 CFR
health and safety benefits, or lack of markets. Id.
3035.16(f). The Postal Service asserts
benefits, to the individual being Total revenues anticipated or received
that the financial documentation and
released, the licensee, and to the public. by the Postal Service from the
workpapers submitted under seal show
Customized Delivery market test must
Dated at Rockville, Maryland, this 3rd day actual and expected revenue and costs
not exceed $10 million in any year
of April, 2017. for the market test. Request at 1, 4.
unless the Commission exempts the
For the Nuclear Regulatory Commission. The Commission invites comments on
market test from that limit.3 If the
Daniel S. Collins, whether the Request complies with
Commission grants an exemption, total
Director, Division of Material Safety, State, applicable statutory and regulatory
revenues anticipated or received by the
Tribal and Rulemaking Programs, Office of requirements, including 39 U.S.C. 3641,
Postal Service from Customized
Nuclear Material Safety and Safeguards. 39 CFR part 3035, Order No. 2224, and
Delivery may not exceed $50 million in
[FR Doc. 2017–07276 Filed 4–10–17; 8:45 am] Order No. 3543. Comments are due no
any year, adjusted for inflation. Id. 39
later than April 26, 2017. The public
BILLING CODE 7590–01–P U.S.C. 3641(e)(2), (g). In its initial notice
portions of these filings can be accessed
for the Customized Delivery market test,
via the Commission’s Web site (http://
the Postal Service requested an
POSTAL REGULATORY COMMISSION www.prc.gov).
exemption from the $10 million revenue
39 U.S.C. 505 requires the
[Docket No. MT2014–1; Order No. 3849] limitation based on then-current
Commission to designate an officer of
the Commission to represent the
Market Test of Experimental Product- 1 Request of the United States Postal Service for
interests of the general public in all
Customized Delivery Exemption from Revenue Limitation on Market Test
of Experimental Product—Customized Delivery, public proceedings (Public
AGENCY: Postal Regulatory Commission. with Portions Filed Under Seal, April 4, 2017 Representative). The Commission
(Request). previously appointed Lauren A.
srobinson on DSK5SPTVN1PROD with NOTICES
ACTION: Notice. 2 See Order Authorizing Customized Delivery
D’Agostino to serve as the Public
Market Test, October 23, 2014 (Order No. 2224); see
SUMMARY: The Commission is noticing a also Order Authorizing Extension of Customized Representative in this proceeding. She
recently-filed Postal Service request for Delivery Market Test and Updating Data Collection
an exemption from the $10 million Plan, September 28, 2016 (Order No. 3543). 4 Notice of the United States Postal Service of
3 See 39 U.S.C. 3641(e). The $10 million annual Market Test of Experimental Product—Customized
annual revenue limitation for the limitation is adjusted by the change in the Delivery, September 23, 2014, at 7.
Customized Delivery market test. This consumer price index for all urban consumers (CPI– 5 Id. The Postal Service calculates an inflation
notice informs the public of the filing, U). Id. 39 U.S.C. 3641(g). adjusted revenue limitation of $11,170,163. Id. at 2.
VerDate Sep<11>2014 20:18 Apr 10, 2017 Jkt 241001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\11APN1.SGM 11APN1](https://thefederalregister.org/doc/82_FR_17533/page/3.svg)
Document Created: 2017-04-11 00:48:52
Document Modified: 2017-04-11 00:48:52
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Request for comment. | |
| Dates | Submit comments by June 12, 2017. Comments received after this date will be considered if it is practical to do so, but the NRC is able to assure consideration only for comments received on or before this date. | |
| Contact | Donna-Beth Howe, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001; telephone: 301-415-7848; email: Donna- [email protected] | |
| FR Citation | 82 FR 17465 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR